albuterol (Armstrong Albuterol HFA) vs fenoterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Armstrong Albuterol HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: April 2028 · NCT07426458 (registry estimate)
No aligned efficacy figure on record for this race.
fenoterol
Marketed by Boehringer Ingelheim
NCT02177370 · Phase 3 · terminated
This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Armstrong Albuterol HFA) | fenoterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00667407 | —Not reported |
| Trough FEV1, change | —Not posted · NCT00667407 | —Not reported |
| ACQ-5, change | —Not posted · NCT00667407 | —Not reported |
| OCS dose reduction | —Not posted · NCT00667407 | —Not reported |
Severe exacerbations, annualised rate
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- fenoterol
- —Not reported
Trough FEV1, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- fenoterol
- —Not reported
ACQ-5, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- fenoterol
- —Not reported
OCS dose reduction
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- fenoterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.
fenoterol: no structured comparison results are available for Asthma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · fenoterol's landscape